RAMM — Ramm Pharma Income Statement
0.000.00%
Last trade - 00:00- CA$5.97m
- CA$5.47m
- CA$4.34m
- 45
- 60
- 41
- 47
Annual income statement for Ramm Pharma, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.44 | 4.12 | 3.9 | 5.07 | 4.34 |
| Cost of Revenue | |||||
| Gross Profit | 1.28 | -0.008 | 0.531 | 0.394 | 1.76 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 13 | 10.8 | 25.2 | 13.2 | 18.7 |
| Operating Profit | -7.58 | -6.64 | -21.3 | -8.16 | -14.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.43 | -7.1 | -21 | -7.71 | -16.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.43 | -7.11 | -21 | -7.72 | -16.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.43 | -7.11 | -21 | -7.72 | -16.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.43 | -7.11 | -21 | -7.72 | -16.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.074 | -0.066 | -0.1 | -0.058 | -0.097 |